Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase EARLY_PHASE1 1

Status

Recruiting 2Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Brain Neoplasms 2Neurotoxicity Syndromes 1Neoplasm Metastasis 1Cognitive Dysfunction 1

Interventions

Cyclophosphamide 297Cisplatin 297Paclitaxel 258Radiotherapy 253Fluorouracil 234Carboplatin 234Docetaxel 231Doxorubicin 212Dexamethasone 164Gemcitabine 155Vincristine 143Etoposide 133Leucovorin 132Capecitabine 129Bevacizumab 129Prednisone 124Rituximab 118Methotrexate 117Cytarabine 108Filgrastim 99Trastuzumab 98Oxaliplatin 96pembrolizumab 81Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Nivolumab 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × Memantine × Clear all
NCT02360215 2025-04-23

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

NRG Oncology

Phase 3 Completed
518 enrolled 40 charts
CNS

Brain Neoplasms, Cognitive Dysfunction

NCT00566852 2017-08-21

Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

Radiation Therapy Oncology Group

Phase 3 Completed
554 enrolled 12 charts
CNS

Brain Neoplasms, Neoplasm Metastasis, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡